Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
News and How Much to Improve in Management of Soft...
share announcement

News and How Much to Improve in Management of Soft Tissue Sarcomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 2943

Special Issue Editors

Dr. Vicente Artigas-Raventós

E-Mail Website
Guest Editor
Surgery Department, Hospital Universitario Sant Pau, Universidad Autonoma de Barcelona, 08035 Barcelona, Spain
Interests: sarcoma; liposarcoma
Dr. José Manuel Asencio

E-Mail Website
Guest Editor
Hepatobiliary Surgery and Liver Transplant Unit, Gregorio Marañón University Hospital, 28007 Madrid, Spain
Interests: sarcoma

Special Issue Information

Dear Colleagues,

Soft tissue sarcomas (STSs) are rare, heterogeneous (>150 subtypes), and of mesenchymal origin. They represent less than 1% of adult tumors and can be located anywhere in the body. Under these conditions, a multidisciplinary approach to sarcomas is mandatory. During the last decades, due to the advancement in chemotherapy and surgical techniques, the survival rate has reached approximately 50% in patients with sarcoma. However, survival rates have not improved during the last 20 years. New biomarkers and therapeutic strategies are necessary to further improve prognosis. Likewise, focus on these patients in reference centers is of vital importance to ensure a correct diagnosis and personalized treatment with a correct incorporation of new diagnostic–therapeutic technologies, and thus to improve the medium- and long-term prognosis of these patients.

We are pleased to invite you to collaborate in this Special Issue of the Soft Tissue Sarcomas. This Special Issue will explore how the sarcomas subgroup relates to the scope of the journal.

In this Special Issue, we propose an approach to the recent progress in diagnosis and treatment and the greater impact on the prognosis of the most prevalent subtypes of sarcomas.

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: immunotherapy in sarcomas, IA and sarcomas, 3D imaging in sarcomas, new surgical approaches in sarcomas, pelvic sarcomas, sarcomas of the cava veins and others venous locations, retroperitoneal sarcomas, medical gestion and referent centers in sarcomas, treatment of desmoid tumors, treatment approaches to metastasic sarcomas, the state-of-the-art in the medical management of sarcomas, etc.

We look forward to receiving your contributions.

Dr. Vicente Artigas-Raventós
Dr. José Manuel Asencio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • soft tissue sarcomas
  • prevalent types
  • multidisciplinary board
  • reference centers
  • news diagnosis methods and treatments
  • implication of IA and 3D in sarcomas
  • implication of minimally aggressive surgical techniques

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

17 pages, 3819 KiB  
Article
DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas
by Kurt Statz-Geary, Andrew Elliott, Steven Bialick, César Serrano, Margaret von Mehren, Matthew Oberley, Andrea P. Espejo-Freire, Priscila Barreto Coelho, Philippos A. Costa, Gina Z. D’Amato, Emily Jonczak, Jonathan C. Trent, Elizabeth Montgomery, David Lombard, Andrew Rosenberg and Aditi Dhir
Cancers 2025, 17(12), 1962; https://doi.org/10.3390/cancers17121962 - 12 Jun 2025
Viewed by 661
Abstract
Background: DNA damage response (DDR) pathway alterations contribute to genomic instability and malignant progression in several cancers. Methods: We retrospectively reviewed molecular profiles from 5309 sarcoma patient samples, including 746 from pediatric/adolescent and young adults (ped/AYA), encompassing 38 histologic subtypes. The gene [...] Read more.
Background: DNA damage response (DDR) pathway alterations contribute to genomic instability and malignant progression in several cancers. Methods: We retrospectively reviewed molecular profiles from 5309 sarcoma patient samples, including 746 from pediatric/adolescent and young adults (ped/AYA), encompassing 38 histologic subtypes. The gene expression profiles were further analyzed for immunotherapy-related biomarker associations, including analysis of the T cell-inflamed score. Results: Pathogenic/likely pathogenic DDR alterations were detected in 15.9% (N = 842) of samples overall and 9.25% (N = 69) of Ped/AYA tumors, with mutations occurring most frequently in ATRX (10.1%). Shorter overall survival was observed for patients with DDR-alterations compared to those with DDR-wildtype tumors (Hazard Ratio = 1.172, 95% CI: 1.068–1.287; p < 0.001). In many subtypes, DDR-mutated tumors were found to have increased rates of immune markers, including PD-L1+, dMMR/MSI-high, and TMB. Conclusions: Our study of somatic DDR-pathway mutations provides a better understanding of the molecular associations across sarcoma subtypes that may aid in developing future prognostic and therapeutic options for these rare cancers. Full article
(This article belongs to the Special Issue News and How Much to Improve in Management of Soft Tissue Sarcomas)
►▼ Show Figures

Figure 1

12 pages, 1022 KiB  
Article
Impact of Severe Postoperative Complications and P-POSSUM Score on Oncological Outcomes in Primary Retroperitoneal Sarcoma: Insights from a Tertiary Cancer Center
by Carlo Abatini, Lorenzo Barberis, Claudio Lodoli, Federica Ferracci, Enrico De Lorenzis, Giorgio D’Annibale, Matteo Aulicino, Michela Quirino, Mariantonietta Di Salvatore, Sergio Alfieri, Fabio Pacelli and Francesco Santullo
Cancers 2025, 17(11), 1787; https://doi.org/10.3390/cancers17111787 - 27 May 2025
Viewed by 638
Abstract
Background: RPS are rare tumors requiring complex surgery. The impact of postoperative complications on long-term outcomes is still debated. This study aimed to identify predictors of severe complications and assess their influence on overall survival (OS) and disease-free survival (DFS). Methods: We retrospectively [...] Read more.
Background: RPS are rare tumors requiring complex surgery. The impact of postoperative complications on long-term outcomes is still debated. This study aimed to identify predictors of severe complications and assess their influence on overall survival (OS) and disease-free survival (DFS). Methods: We retrospectively analyzed 61 patients who underwent curative surgery for primary RPS between 2013 and 2023 at a tertiary cancer center. Patients with pelvic or recurrent sarcomas were excluded. Severe complications were defined as Clavien–Dindo (CD) grade ≥ 3A. Cox regression and Fine–Gray competing risk models were used for OS and DFS, respectively. Sarculator and P-POSSUM scores were included in multivariable models. Results: Severe complications occurred in 14.8% of patients; 30-day mortality was 1.6%. Predictive factors for complications included longer operative time, gastric resection, intraoperative complications, and transfusions. In multivariable analysis, Sarculator was significantly associated with both DFS (HR 0.97; p = 0.004) and OS (HR 0.97; p = 0.008). The P-POSSUM mortality score predicted OS (HR 1.12; p = 0.002). Severe complications were not independently associated with DFS or OS. Conclusions: In this cohort, severe complications did not impact long-term oncological outcomes. Prognostic tools such as Sarculator and P-POSSUM may enhance risk stratification in RPS surgery. Prospective validation is warranted. Full article
(This article belongs to the Special Issue News and How Much to Improve in Management of Soft Tissue Sarcomas)
►▼ Show Figures

Figure 1

Other

Jump to: Research

29 pages, 342 KiB  
Guidelines
Ibero-American Consensus for the Management of Liver Metastases of Soft Tissue Sarcoma: Updated Review and Clinical Recommendations
by Raquel Lopes-Brás, Paula Muñoz, Eduardo Netto, Juan Ángel Fernández, Mario Serradilla-Martín, Pablo Lozano, Miguel Esperança-Martins, Gerardo Blanco-Fernández, José Antonio González-López, Francisco Cristóbal Muñoz-Casares, Isabel Fernandes, José Manuel Asencio-Pascual and Hugo Vasques
Cancers 2025, 17(8), 1295; https://doi.org/10.3390/cancers17081295 - 11 Apr 2025
Viewed by 1291
Abstract
Liver metastases from soft tissue sarcoma (STS) (excluding gastrointestinal stromal tumors) are rare and more commonly arise from retroperitoneal and intra-abdominal primary sites. Chemotherapy remains the mainstay of treatment for disseminated disease, but its effectiveness is limited and patients typically have a dismal [...] Read more.
Liver metastases from soft tissue sarcoma (STS) (excluding gastrointestinal stromal tumors) are rare and more commonly arise from retroperitoneal and intra-abdominal primary sites. Chemotherapy remains the mainstay of treatment for disseminated disease, but its effectiveness is limited and patients typically have a dismal prognosis with short survival. However, when metastases are confined to the liver (without pulmonary involvement), some patients may benefit from local techniques, either surgical or nonsurgical, that can provide long periods of disease-free survival. Due to the rarity of STS, especially with liver metastases, and the heterogeneity of histologies and biological behavior, there is a lack of standardized treatment guidelines and universally accepted criteria for this specific setting. To fill this gap, a multidisciplinary working group of experts in sarcoma and liver surgery reviewed the literature and available evidence and developed a set of clinical recommendations to be voted and discussed in the I Ibero-American Consensus on the Management of Metastatic Sarcoma, held at the III Spanish-Portuguese Update Meeting on the Treatment of Sarcomas in May 2024. Herein, the voting results of this meeting and the resulting consensus recommendations are presented, and their applicability, strengths, and limitations are discussed. Full article
(This article belongs to the Special Issue News and How Much to Improve in Management of Soft Tissue Sarcomas)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop